Skip to main content
TECON BIOLOGY Co.LTD logo

TECON BIOLOGY Co.LTD — Investor Relations & Filings

Ticker · 002100 ISIN · CNE000001PZ9 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,493 across all filing types
Latest filing 2023-04-28 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002100

About TECON BIOLOGY Co.LTD

https://www.tcsw.com.cn

TECON BIOLOGY Co.LTD operates an integrated industrial chain focused on animal health and nutrition. The company specializes in the research, development, and manufacturing of veterinary biological products, including a comprehensive range of vaccines and diagnostic reagents for livestock. Its operations encompass the production of high-quality animal feed and the management of large-scale breeding programs, with a primary focus on pig farming and meat processing. By leveraging advanced biotechnology and standardized production systems, the company provides comprehensive solutions for livestock management and food safety. Key activities include the formulation of specialized animal nutrition products and the implementation of rigorous biosecurity protocols across its facilities to ensure the quality and reliability of its agricultural outputs.

Recent filings

Filing Released Lang Actions
中信建投证券股份有限公司关于天康生物股份有限公司2022年度募集资金存放与使用情况的专项核查报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from a securities company (中信建投证券股份有限公司) about the 2022 annual special audit on the deposit and use of raised funds by 天康生物股份有限公司. It includes extensive financial data on fundraising amounts, usage, balances, regulatory compliance, and audit opinions. The document references specific fundraising events (2017 convertible bonds, 2020 private stock issuance), detailed tables of fund usage, changes in investment projects, and audit verification by an accounting firm. The content is focused on the management, storage, and use of raised capital funds, with no indication of it being a general annual report, earnings release, or other types of filings. This type of document aligns with an Audit Report / Information (AR) as it is a standalone audit and verification report on the use of raised funds, not a full annual report or earnings release. The length and detail confirm it is the report itself, not just an announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2022
2023-04-28 Chinese
2022年度监事会工作报告
Board/Management Information Classification · 95% confidence The document is titled as the '2022年度监事会工作报告' which translates to '2022 Supervisory Board Work Report'. It details the supervisory board's activities, meetings, and opinions on company operations, financial status, internal controls, related party transactions, and compliance with laws and regulations during the 2022 fiscal year. The document is a formal report from the supervisory board, not an announcement or a brief summary. It contains detailed oversight and governance information rather than financial statements or earnings data. This aligns with the category of Board/Management Information (MANG), which includes announcements related to company governance and supervisory board activities. The document is 3152 characters long, which is relatively short but contains substantive content about supervisory board work rather than just an announcement of a report publication. Therefore, the best fit is MANG.
2023-04-28 Chinese
2023年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '天康生物股份有限公司2023 年第一季度报告' which translates to 'Tiankang Biological Co., Ltd. 2023 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on non-recurring gains and losses. The document explicitly states it is a quarterly report for the first quarter of 2023 and is unaudited. The length of the document (over 12,000 characters) and the presence of comprehensive financial statements confirm it is a full interim/quarterly financial report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2023
2023-04-28 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the eighth board of directors' fifth meeting of Tian Kang Biological Co., Ltd. It includes multiple agenda items such as approval of the 2022 annual report, financial statements, profit distribution plan, internal control reports, appointment of auditors, remuneration of directors and senior management, and other corporate governance matters. The document repeatedly states that these resolutions will be submitted to the 2022 annual general meeting for approval. The document is not the annual report itself but a formal announcement of board meeting decisions related to the annual report and other governance matters. It is a typical Board/Management Information announcement, as it reports on board meeting resolutions and management reports rather than the full annual report or financial statements. The document length (6401 characters) and content confirm it is not a brief report publication announcement or a certification. Therefore, the appropriate classification is Board/Management Information (MANG).
2023-04-28 Chinese
中信建投证券股份有限公司关于天康生物股份有限公司2023年度日常关联交易预计的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from a sponsoring institution (中信建投证券股份有限公司) regarding the expected daily related-party transactions for the year 2023 of 天康生物股份有限公司. It includes descriptions of the related parties, transaction amounts, pricing principles, decision-making procedures, and opinions from independent directors and the supervisory board. The document is regulatory in nature, focusing on compliance and verification of related-party transactions rather than presenting financial statements or earnings data. It does not contain financial results or management discussion typical of annual or interim reports, nor is it a simple announcement or certification. This type of document fits best under Regulatory Filings (RNS), as it is a compliance-related disclosure that does not fit other specific categories.
2023-04-28 Chinese
关于2023年日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's expected related party transactions for the year 2023. It includes details about the nature of the transactions, pricing principles, estimated amounts, and opinions from the board of directors, independent directors, supervisory board, and the sponsor institution. The document does not contain comprehensive financial statements or detailed financial performance data typical of an annual or interim report. It is a regulatory announcement about expected related party transactions, which is a common disclosure for listed companies to inform shareholders and the market about potential related party dealings. Therefore, it fits best under the category of Regulatory Filings (RNS), as it is a compliance disclosure that does not constitute a full financial report or other specific filing types.
2023-04-28 Chinese

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.